Evaluation of Nitisinone in the Indian Patients of Hereditary Tyrosinemia Type 1
Not Applicable
- Conditions
- Health Condition 1: E72- Other disorders of amino-acid metabolism
- Registration Number
- CTRI/2023/05/052626
- Lead Sponsor
- Department of Science & Technology DST
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Molecularly and/or biochemically proven patients with hereditary tyrosinemia type 1
Exclusion Criteria
Poor compliance
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Pharmacokinetic profile for the NTBC in Indian patients with Hereditary Tyrosinemia type 1Timepoint: 0, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, and 36 months
- Secondary Outcome Measures
Name Time Method Pharmacodynamic profile for the NTBC in Indian patients with Hereditary Tyrosinemia type 1Timepoint: 0, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, and 36 months